Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience

Combining cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors with endocrine therapies in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in the first and second lines has emerged as optimal treatment strategy and has implications rel...

Full description

Bibliographic Details
Main Authors: Irina V. Kolyadina, Inna P. Ganshina, Svetlana V. Kuzmicheva, Asiiat I. Tekeeva, James D. Kolokolov, Mikhail V. Volkonskii, Irina V. Poddubnaya
Format: Article
Language:Russian
Published: IP Habib O.N. 2020-07-01
Series:Современная онкология
Subjects:
advanced breast cancer
hormonal therapy with cdk 4/6 inhibitors
hormone resistance
eribulin chemotherapy
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/34960/23375

Similar Items

Similar Items